Monica Bartucci
Overview
Explore the profile of Monica Bartucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
985
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patrizii M, Bartucci M, Pine S, Sabaawy H
Front Oncol
. 2018 Feb;
8:23.
PMID: 29484285
Despite substantial effort and resources dedicated to drug discovery and development, new anticancer agents often fail in clinical trials. Among many reasons, the lack of reliable predictive preclinical cancer models...
2.
Bartucci M, Hussein M, Huselid E, Flaherty K, Patrizii M, Laddha S, et al.
Target Oncol
. 2017 Jun;
12(4):449-462.
PMID: 28589491
Background: Hepatocellular carcinoma (HCC) represents one of the most lethal cancers worldwide due to therapy resistance and disease recurrence. Tumor relapse following treatment could be driven by the persistence of...
3.
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H
Front Cell Dev Biol
. 2016 Sep;
4:74.
PMID: 27583246
[This corrects the article DOI: 10.3389/fcell.2016.00064.].
4.
Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H
Front Cell Dev Biol
. 2016 Jul;
4:64.
PMID: 27446916
Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in Western men. Despite its prevalence, PCa has proven very difficult to propagate...
5.
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, et al.
Clin Cancer Res
. 2016 Jun;
22(24):6176-6191.
PMID: 27307599
Purpose: Current prostate cancer management calls for identifying novel and more effective therapies. Self-renewing tumor-initiating cells (TICs) hold intrinsic therapy resistance and account for tumor relapse and progression. As BMI-1...
6.
Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, et al.
PLoS One
. 2016 Mar;
11(3):e0149872.
PMID: 26930412
Cervical cancer cells commonly harbour a defective G1/S checkpoint owing to the interaction of viral oncoproteins with p53 and retinoblastoma protein. The activation of the G2/M checkpoint may thus become...
7.
8.
Maugeri-Sacca M, Barba M, Pizzuti L, Vici P, Di Lauro L, Dattilo R, et al.
Expert Rev Mol Med
. 2015 Jul;
17:e14.
PMID: 26136233
The Hippo signalling is emerging as a tumour suppressor pathway whose function is regulated by an intricate network of intracellular and extracellular cues. Defects in the signal cascade lead to...
9.
Vici P, Mottolese M, Pizzuti L, Barba M, Sperati F, Terrenato I, et al.
Oncotarget
. 2014 Oct;
5(20):9619-25.
PMID: 25294813
Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in breast cancer and it has been associated with breast cancer stem cells. Additionally, TAZ expression has...
10.
Maugeri-Sacca M, Bartucci M, Pagliuca A, Patrizii M, Signore M, De Maria R
Curr Pharm Des
. 2013 Oct;
20(24):3973-81.
PMID: 24138717
The advent of molecular targeted agents is changing the treatment of solid tumors. In non-small-cell lung cancer, compounds directed against oncogenic proteins offer novel therapeutic opportunities for a fraction of...